Literature DB >> 22865093

B-cell receptor pathobiology and targeting in NHL.

Ines M Macias-Perez1, Ian W Flinn.   

Abstract

B-cell receptor signaling plays varied and critical roles in B-cell development, homeostasis and disease. The key players of the pathway and its many signaling modulators have been identified as well as some of the mechanisms by which the pathway is regulated. With the increased incidence of non-Hodgkin's lymphoma in recent years, there is a clear clinical need for novel agents to offer new options in resistant disease to potentially improve outcomes in curative settings. With the tremendous insight gained in the last 2 decades from basic science research, our understanding of the pathobiology of the B-cell receptor is leading to the discovery and clinical development of many new therapeutic targets such as Syk, Bruton's tyrosine kinase, and phosphatidylinositol 3-kinase. This review will emphasize contemporary and salient findings on novel agents targeting the B-cell receptor signaling pathway for the treatment of non-Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865093     DOI: 10.1007/s11912-012-0254-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  38 in total

Review 1.  BLNK: connecting Syk and Btk to calcium signals.

Authors:  T Kurosaki; S Tsukada
Journal:  Immunity       Date:  2000-01       Impact factor: 31.745

2.  PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma.

Authors:  J Abubaker; P P Bavi; S Al-Harbi; A K Siraj; F Al-Dayel; S Uddin; K Al-Kuraya
Journal:  Leukemia       Date:  2007-07-26       Impact factor: 11.528

Review 3.  B cell signaling and tumorigenesis.

Authors:  Hassan Jumaa; Rudolf W Hendriks; Michael Reth
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 4.  Receptors, subcellular compartments and the regulation of peripheral B cell responses: the illuminating state of anergy.

Authors:  Marcus R Clark; Azusa Tanaka; Sarah E Powers; Margaret Veselits
Journal:  Mol Immunol       Date:  2010-12-07       Impact factor: 4.407

5.  Syk tyrosine kinase required for mouse viability and B-cell development.

Authors:  A M Cheng; B Rowley; W Pao; A Hayday; J B Bolen; T Pawson
Journal:  Nature       Date:  1995-11-16       Impact factor: 49.962

6.  Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk.

Authors:  M Turner; P J Mee; P S Costello; O Williams; A A Price; L P Duddy; M T Furlong; R L Geahlen; V L Tybulewicz
Journal:  Nature       Date:  1995-11-16       Impact factor: 49.962

7.  Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice.

Authors:  D J Rawlings; D C Saffran; S Tsukada; D A Largaespada; J C Grimaldi; L Cohen; R N Mohr; J F Bazan; M Howard; N G Copeland
Journal:  Science       Date:  1993-07-16       Impact factor: 47.728

8.  Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.

Authors:  C Yang; P Lu; F Y Lee; A Chadburn; J C Barrientos; J P Leonard; F Ye; D Zhang; D M Knowles; Y L Wang
Journal:  Leukemia       Date:  2008-07-03       Impact factor: 11.528

9.  The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas.

Authors:  Pinelopi Argyriou; Panagiota Economopoulou; Sotirios Papageorgiou
Journal:  Adv Hematol       Date:  2011-06-16

10.  B cell development is arrested at the immature B cell stage in mice carrying a mutation in the cytoplasmic domain of immunoglobulin beta.

Authors:  A Reichlin; Y Hu; E Meffre; H Nagaoka; S Gong; M Kraus; K Rajewsky; M C Nussenzweig
Journal:  J Exp Med       Date:  2001-01-01       Impact factor: 14.307

View more
  4 in total

1.  Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma.

Authors:  Lei Gao; Zhenjun Feng; Qiang Li; Lianqing Li; Lei Chen; Taiwu Xiao
Journal:  Tumour Biol       Date:  2013-11-19

2.  Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins.

Authors:  Stephen Middle; Sarah E Coupland; Azzam Taktak; Victoria Kidgell; Joseph R Slupsky; Andrew R Pettitt; Kathleen J Till
Journal:  Exp Hematol Oncol       Date:  2015-04-01

Review 3.  Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.

Authors:  Bartosz Puła; Aleksandra Gołos; Patryk Górniak; Krzysztof Jamroziak
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

Review 4.  Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.

Authors:  Mark P Chao
Journal:  Cancer Manag Res       Date:  2013-08-23       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.